Eva Fortea Verdejo

Q: What is Eva Fortea Verdejo's success rate?

Eva Fortea Verdejo currently has a success rate of 95.76731790095813.

Q: What is the average return of Eva Fortea Verdejo's calls?

Their stock ratings have generated an average return of 36.96427262108688.

Wells Fargo | Healthcare

Eva Fortea Verdejo is an analyst from Wells Fargo specializing in the Healthcare sector. Ranked #281 out of 4613 analysts, they have issued 29 stock ratings with a success rate of 95.77% and an average return of 36.96%.

Eva Fortea Verdejo has a well-established track record, with 29 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 95.77% and an average return of 36.96%, underscoring their expertise and ability to identify winning opportunities for investors.

#281

Out of 4613

Total Ratings

+95.77%

Success Rate

+36.96%

Average Return

Recent Ratings Analysis

IDYA

Buy

Apr 14, 2026

Target

$48.00

Current

$32.35

Performance

0.00%

Eva Fortea Verdejo rated IDYA as Overweight on Apr 14, 2026, setting a price target of 48. Shares have remained stable near 32.35, leaving the 48 target still in play.

RVMD

Buy

Apr 14, 2026

Target

$167.00

Current

$147.01

Performance

0.00%

On Apr 14, 2026, RVMD was given a Overweight rating by Eva Fortea Verdejo, with a target price of 167. The stock traded sideways with a 0.00% move, keeping the bullish thesis unresolved.

BCAX

Hold

Mar 31, 2026

Target

$16.00

Current

$22.98

Performance

15.54%

BCAX received a Equal-Weight rating from Eva Fortea Verdejo on Mar 31, 2026, aiming for 16. Investors saw gains of 15.54% that the cautious stance didn’t fully capture.

NUVL

Buy

Mar 30, 2026

Target

$116.00

Current

$105.02

Performance

8.58%

On Mar 30, 2026, Eva Fortea Verdejo published a Overweight outlook on NUVL, with a target of 116. Shares gained 8.58%, underscoring the accuracy of the bullish outlook toward 116.

STRO

Buy

Mar 24, 2026

Target

$27.00

Current

$28.78

Performance

22.10%

Eva Fortea Verdejo on Mar 24, 2026 assigned STRO a Overweight rating, with a price target of 27. The Buy call aligned well with market performance, producing a gain of 22.10%.

RLAY

Buy

Mar 17, 2026

Target

$17.00

Current

$14.75

Performance

43.76%

On Mar 17, 2026, Eva Fortea Verdejo reaffirmed RLAY with a Overweight rating, targeting 17. The recommendation was supported by strong follow-through as the stock rose from 14.75 to 14.75.

GMAB

Buy

Mar 02, 2026

Target

$40.00

Current

$29.06

Performance

-1.99%

GMAB was rated Overweight by Eva Fortea Verdejo on Mar 02, 2026, with a price objective of 40. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

KNSA

Buy

Feb 25, 2026

Target

$53.00

Current

$46.92

Performance

9.73%

On Feb 25, 2026, Eva Fortea Verdejo initiated coverage on KNSA with a Overweight rating and target of 53. The stock’s climb of 9.73% since the call highlights the foresight in the rating.

RCUS

Hold

Feb 12, 2026

Target

$30.00

Current

$23.01

Performance

15.28%

Eva Fortea Verdejo issued a Equal-Weight recommendation for RCUS on Feb 12, 2026, price target set at 30. A neutral call gave way to stronger-than-expected performance, closing in on 30.

EXEL

Hold

Feb 11, 2026

Target

$35.00

Current

$45.86

Performance

6.80%

On Feb 11, 2026, EXEL was evaluated by Eva Fortea Verdejo, who gave a Equal-Weight rating and target of 35. Investors who stayed in despite the Hold saw upside of 6.80%.

ZYME

Buy

Dec 12, 2025

Target

$33.00

Current

$26.98

Performance

5.89%

Eva Fortea Verdejo rated ZYME as Overweight on Dec 12, 2025, setting a price target of 33. The call has proven timely, with shares rising 5.89% toward the price target of 33.

IMCR

Buy

Oct 31, 2025

Target

$60.00

Current

$31.69

Performance

-4.23%

On Oct 31, 2025, IMCR was given a Overweight rating by Eva Fortea Verdejo, with a target price of 60. The stock traded sideways with a -4.23% move, keeping the bullish thesis unresolved.

MRUS

Hold

Sep 30, 2025

Target

$97.00

Current

$90.00

Performance

-4.41%

MRUS received a Equal-Weight rating from Eva Fortea Verdejo on Sep 30, 2025, aiming for 97. Shares remained flat at 90, aligning with the neutral rating.

ITOS

Hold

Aug 07, 2025

Target

$11.00

Current

$10.15

Performance

0.20%

On Aug 07, 2025, Eva Fortea Verdejo published a Equal-Weight outlook on ITOS, with a target of 11. Sideways action left the Hold view intact, with no major move since 10.15.

XNCR

Buy

Aug 07, 2025

Target

$27.00

Current

$12.51

Performance

70.90%

Eva Fortea Verdejo on Aug 07, 2025 assigned XNCR a Overweight rating, with a price target of 27. The Buy call aligned well with market performance, producing a gain of 70.90%.

Frequency Asked Questions

Who is Eva Fortea Verdejo?

Eva Fortea Verdejo is an analyst from Wells Fargo specializing in the Healthcare sector.

What is Eva Fortea Verdejo's success rate?

Eva Fortea Verdejo currently has a success rate of +95.77%.

How many ratings has Eva Fortea Verdejo issued?

Eva Fortea Verdejo has issued 29 stock ratings so far.

What is the average return of Eva Fortea Verdejo's calls?

Their stock ratings have generated an average return of +36.96%.

What is Eva Fortea Verdejo's ranking?

Eva Fortea Verdejo is ranked #281 out of 4613 analysts.

What types of ratings does Eva Fortea Verdejo give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Eva Fortea Verdejo?

You can follow Eva Fortea Verdejo by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Eva Fortea Verdejo?

Their latest rating was a Buy on IDYA issued on 2026-04-14.